IgM does not cross the placenta. It is the largest antibody in the human body, and its size and shape physically prevent it from passing through the placental barrier. This is why finding IgM in a newborn’s blood is clinically significant: if it’s there, the baby made it, not the mother.
Why IgG Crosses but IgM Cannot
The placenta has a dedicated transport system for moving antibodies from mother to baby, but it only works for one type: IgG. A specialized receptor called the neonatal Fc receptor (FcRn) sits on the surface of placental cells and acts like a selective shuttle. It binds to IgG molecules in the mother’s blood, pulls them through the placental tissue, and releases them into fetal circulation on the other side. The binding depends on a pH-sensitive mechanism: FcRn grabs IgG in the mildly acidic environment inside cellular compartments, then releases it at the neutral pH of the bloodstream.
IgM can’t use this shuttle for two reasons. First, it lacks the specific structural region that FcRn recognizes. The receptor latches onto a particular hinge area on IgG that IgM simply doesn’t have. Second, IgM circulates as a pentamer, meaning five antibody units joined together in a ring. This makes it roughly five times larger than a single IgG molecule, far too bulky to be transported through placental cells even if a receptor could grab it.
When IgG Transfer Happens During Pregnancy
Maternal IgG begins crossing the placenta surprisingly early. It can be detected in fetal blood as soon as 8 to 10 weeks of gestation, though the amounts are small at first. By 17 to 22 weeks, the fetus has roughly 10% of the mother’s IgG levels. By 30 weeks, that rises to about 50%.
The real surge happens in the third trimester. By 37 to 40 weeks, IgG levels in cord blood often exceed the mother’s own serum levels in healthy, full-term pregnancies. This likely reflects the growing surface area of the placenta as pregnancy progresses, giving more room for antibody uptake. It also means premature babies miss out on a significant portion of this passive immunity, leaving them more vulnerable to infections in early life.
What IgM in a Newborn’s Blood Means
Because IgM doesn’t cross the placenta, any IgM found in a newborn’s cord blood was produced by the baby’s own immune system. Elevated cord blood IgM (above 20 mg/dL) raises suspicion for an intrauterine infection, meaning the baby was exposed to a pathogen before birth and mounted an immune response in the womb.
This principle is the foundation of the TORCH screen, a panel of tests used to check newborns for infections acquired during pregnancy. TORCH stands for toxoplasmosis, rubella, cytomegalovirus (CMV), herpes simplex, and sometimes syphilis. When high levels of pathogen-specific IgM are found in the baby’s blood, it serves as evidence that the baby was infected in utero, not just carrying the mother’s antibodies. For infections like CMV and rubella, finding virus-specific IgM in cord blood is considered definitive evidence of congenital infection.
Reliability of Neonatal IgM Testing
IgM-based testing for congenital infections is useful but not perfect. The accuracy varies depending on the specific infection and the type of test used. For congenital syphilis, older testing methods detected between 64% and 93% of true cases. Newer immunoblot assays perform better, with sensitivities ranging from about 87% to 95% and specificities above 97% in several commercial tests. One small study found 100% detection in cases of congenital syphilis with neurologic involvement.
The gap between these numbers matters. A negative IgM result doesn’t always rule out infection, particularly if the baby’s immune system hasn’t had enough time to produce detectable antibodies. Clinicians typically combine IgM results with physical examination findings and other lab tests rather than relying on a single result.
Rare Exceptions and Placental Leakage
In unusual circumstances, small amounts of IgM may appear in cord blood without the baby having produced it. Research during the COVID-19 pandemic documented cases where placental damage, including blood clots between the villi and inflammation of the placental tissue, appeared to compromise the barrier between maternal and fetal blood. In these cases, maternal IgM was found at similar levels in both maternal blood and cord blood, consistent with leakage rather than fetal immune production.
These situations involve significant placental pathology and are not considered normal transfer. They highlight that while the general rule holds firmly (IgM does not cross an intact placenta), physical damage to the placental barrier can allow passive leakage of larger molecules. This is an important distinction when interpreting cord blood results in pregnancies complicated by placental disease or hemorrhage.